DCCR
Search documents
SLNO EQUITY ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
TMX Newsfile· 2026-03-30 22:16
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - March 30, 2026) - ...
SLNO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Prnewswire· 2026-03-28 14:44
<!doctype html> <!-- For structured data --> <!-- For language declaration --> SLNO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) WilsonEncourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in S ...
SLNO INVESTOR ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
TMX Newsfile· 2026-03-27 14:10
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - March 27, 2026) - ...
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
TMX Newsfile· 2026-03-20 14:07
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Soleno Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety and efficacy of its drug candidate DCCR [2][4]. Group 1: Allegations and Legal Actions - The complaint alleges that Soleno and its executives made false statements and failed to disclose significant safety concerns related to the DCCR clinical trial, including issues of excess fluid retention [4]. - The company is facing a federal securities class action, with a deadline of May 5, 2026, for investors to seek the role of lead plaintiff [2][8]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Stock Price Impact - Following a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell from over $77 per share to approximately $68 per share, a decline of nearly 12% [5]. - After a patient death was disclosed on September 10, 2025, the stock price dropped from more than $70 per share to about $57 per share, a decline of approximately 19% [6]. - On November 4, 2025, Soleno reported financial results indicating that the earlier report disrupted the launch of DCCR, leading to a one-day stock price decline of approximately 27%, from nearly $64 to about $47 per share [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline
Globenewswire· 2026-03-19 12:11
NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The Soleno Class Action Lawsuit? Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?Did you purchase your shares between March 26, 2025 and August 4, 2025, inclus ...
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Prnewswire· 2026-03-18 19:38
Core Viewpoint - Soleno Therapeutics, Inc. is facing a securities fraud class action lawsuit due to alleged misrepresentation of safety concerns related to its DCCR drug during clinical trials [3]. Group 1: Lawsuit Details - The lawsuit claims that from March 26, 2025, to November 4, 2026, Soleno failed to disclose significant safety concerns regarding the DCCR drug, particularly issues related to excess fluid retention in trial participants [3]. - The complaint asserts that the administration of DCCR posed materially greater safety risks than what was disclosed by the company and its executives [3]. - It is alleged that DCCR had lower commercial viability and undisclosed risks, including potential adverse events post-launch, which were not communicated to investors [3]. Group 2: Investor Participation - Investors who suffered losses related to Soleno Therapeutics have the opportunity to lead the class action lawsuit, with a deadline for participation set for May 5, 2026 [2]. - Interested investors can contact the Law Offices of Frank R. Cruz for more information on how to participate in the lawsuit [4].
SLNO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Globenewswire· 2026-03-18 17:37
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Soleno between March 26, 2025 and November 4, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Faruqi & ...
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
Globenewswire· 2026-03-17 12:18
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive. Should You Join The Soleno Class Action Lawsuit? Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?Did you purchase your shares between Marc ...
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
Prnewswire· 2026-03-16 18:07
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Soleno Therapeutics, Inc. and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][4]. Group 1: Allegations Against Soleno Therapeutics - The complaint alleges that Soleno and its executives violated federal securities laws by making false or misleading statements and failing to disclose significant safety concerns related to the Phase 3 clinical trial program for DCCR [4][11]. - Specific allegations include that the administration of DCCR posed materially greater safety risks than disclosed, and that DCCR had materially lower commercial viability due to undisclosed risks [4][11]. Group 2: Stock Price Impact - Following a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell from over $77 per share to approximately $68 per share, a decline of nearly 12% over two trading days [5][11]. - After a patient death was disclosed on September 10, 2025, the stock price dropped from more than $70 per share to about $57 per share, a decline of approximately 19% over two trading days [6][11]. - On November 4, 2025, Soleno reported financial results indicating that the earlier report disrupted the launch trajectory of DCCR, leading to a one-day stock price decline of approximately 27%, from nearly $64 per share to about $47 per share [7][11]. Group 3: Legal Proceedings - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class [8][11]. - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [8][11]. Group 4: Call for Information - Faruqi & Faruqi encourages anyone with information regarding Soleno's conduct, including whistleblowers and former employees, to contact the firm [9][11].
Soleno Therapeutics Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action filed by Robbins Geller Rudman & Dowd LLP
Businesswire· 2026-03-13 09:10
Core Viewpoint - The Soleno complaint alleges that the Phase 3 clinical trial program for DCCR has downplayed, misrepresented, and/or concealed safety concerns [1] Group 1 - The complaint specifically targets the safety concerns related to the DCCR clinical trial [1]
